摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1S)-1-[3-[(1Z,2S,4aR,8aS)-7-cyano-2,5,5,8a-tetramethyl-6-oxo-1-(2-oxopropylidene)-4,4a-dihydro-3H-naphthalen-2-yl]-3-methylbutyl]-2,4,4-trimethyl-N-(2,2,2-trifluoroethyl)cyclohexane-1-carboxamide

中文名称
——
中文别名
——
英文名称
(1S)-1-[3-[(1Z,2S,4aR,8aS)-7-cyano-2,5,5,8a-tetramethyl-6-oxo-1-(2-oxopropylidene)-4,4a-dihydro-3H-naphthalen-2-yl]-3-methylbutyl]-2,4,4-trimethyl-N-(2,2,2-trifluoroethyl)cyclohexane-1-carboxamide
英文别名
——
(1S)-1-[3-[(1Z,2S,4aR,8aS)-7-cyano-2,5,5,8a-tetramethyl-6-oxo-1-(2-oxopropylidene)-4,4a-dihydro-3H-naphthalen-2-yl]-3-methylbutyl]-2,4,4-trimethyl-N-(2,2,2-trifluoroethyl)cyclohexane-1-carboxamide化学式
CAS
——
化学式
C35H51F3N2O3
mdl
——
分子量
604.8
InChiKey
BRCQBLGJUCLKEC-FRBJBIBESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    8.7
  • 重原子数:
    43
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.77
  • 拓扑面积:
    87
  • 氢给体数:
    1
  • 氢受体数:
    7

文献信息

  • ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH SATURATION IN THE C-RING
    申请人:REATA PHARMACEUTICALS, INC.
    公开号:US20140179928A1
    公开(公告)日:2014-06-26
    This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
  • Compositions and Methods of Treatment of Corneal Endothelium Disorders
    申请人:The Schepens Eye Research Institute, Inc.
    公开号:US20160175380A1
    公开(公告)日:2016-06-23
    This application discloses pharmaceutical compositions (e.g., oral, parenteral or topical ophthalmic formulations) for treating Fuchs endothelial corneal dystrophy (FECD) with one or more Nrf2 activators and/or mitochondrially targeted antioxidants. The compositions may be topically administered to the eye and are effective in the treatment of FECD. The invention further provides methods of treating FECD by in a subject in need of such treatment by topical application of one or more Nrf2 activators and/or mitochondrially of the invention.
  • US9090574B2
    申请人:——
    公开号:US9090574B2
    公开(公告)日:2015-07-28
  • US9757359B2
    申请人:——
    公开号:US9757359B2
    公开(公告)日:2017-09-12
  • USRE45325E1
    申请人:——
    公开号:USRE45325E1
    公开(公告)日:2015-01-06
查看更多